Multiple Myeloma

gilead-acquires-arcellx-for-7-8-billion-to-enhance-car-t-therapy

Gilead Acquires Arcellx for $7.8 Billion to Enhance CAR-T Therapy

Editorial 23 February, 2026

Gilead Sciences has announced its acquisition of Arcellx, a partner in its cell therapy...

researchers-explore-new-car-t-cell-targets-in-multiple-myeloma

Researchers Explore New CAR T-Cell Targets in Multiple Myeloma

Editorial 9 January, 2026

Recent discussions among leading researchers have spotlighted the potential of CAR T-cell therapy to...

innovative-ccr4-strategy-shows-promise-in-t-cell-lymphoma-treatment

Innovative CCR4 Strategy Shows Promise in T-Cell Lymphoma Treatment

Editorial 30 September, 2025

Researchers have successfully employed a CCR4-directed strategy to achieve durable responses in patients with...